Clinical Research Directory

Inclusion Criteria: * Pathologically confirmed patients with locally-advanced or metastatic ALK-positive non-small cell lung cancer. * Currently receiving, or planned to receive treatment with Iruplinalkib. * Subjects had imaging reports of chest and abdominal enhanced CT and brain MRI within 42 days prior to the first dose of Iruplinalkib as 1L treatment for locally-advanced or metastatic ALK-positive non-small cell lung cancer. * Subjects had routine and biochemical reports within 30 days prior to the first dose of Iruplinalkib as 1L treatment for locally-advanced or metastatic ALK-positive non-small cell lung cancer. Exclusion Criteria: * Patients who had previously been treated with ALK-TKI, but who had previously only been treated with ALK-TKI as neoadjuvant and/or adjunctive treatment could be enrolled. * Mental disorder or inability to cooperate with examination or follow-up. * Women known to be pregnant or lactating.